Pipeline Report: April 2022 | Articles

Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer

April 11th 2022

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

GD2-Directed CAR T-Cell Therapy Elicits Durable Benefit in H3K27M-Mutated Diffuse Intrinsic Pontine Gliomas

April 10th 2022

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC

April 10th 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Temferon Displays Activity in Glioblastoma

April 8th 2022

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

Nivolumab Plus PD-L1/IDO Peptide Vaccine Displays Impressive Efficacy in Metastatic Melanoma

April 8th 2022

Nivolumab in combination with a PD-L1/IDO peptide vaccine displayed encouraging efficacy and survival results among patients with metastatic melanoma.

Zanubrutinib Continues to Show Safety, Efficacy in Relapsed/Refractory MCL

April 8th 2022

Zanubrutinib monotherapy continues to demonstrate durable responses with an acceptable toxicity profile in patients with relapsed or refractory mantle cell lymphoma.

Relmacabtagene Autoleucel Gets Breakthrough Therapy Designation for MCL in China

April 7th 2022

The China National Medical Products Administration’s Center for Drug Evaluation has granted a breakthrough therapy designation to relmacabtagene autoleucel for use in the treatment of patients with mantle cell lymphoma.

Venetoclax Consolidation Does Not Prevent Loss of MRD Response Following First-Line Venetoclax/Obinutuzumab for CLL

April 7th 2022

Venetoclax consolidation following first-line treatment with venetoclax and obinutuzumab did not reduce loss of minimal residual disease response vs MRD-guided venetoclax consolidation in previously untreated patients with chronic lymphocytic leukemia.

RP1/Nivolumab Combo Produces Deep, Durable Responses in Melanoma and Other Skin Cancers

April 6th 2022

The combination of the oncolytic vaccine vusolimogene oderparepvec and nivolumab continued to drive encouraging responses with acceptable tolerability in patients with melanoma and other skin cancers.

FDA Places Partial Clinical Hold on Study Evaluating Emavusertib in Relapsed/Refractory AML or High-Risk MDS

April 4th 2022

The FDA has placed a partial clinical hold on the phase 1/2a TakeAim Leukemia trial, which is evaluating emavusertib as a single agent and in combination with azacitidine or venetoclax in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

FDA Grants Fast Track Status to PRGN-3006 for Relapsed/Refractory AML

April 4th 2022

The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia.

Selpercatinib Continues to Provide Clinically Meaningful Benefit in Advanced RET Fusion–Positive NSCLC

April 2nd 2022

Selpercatinib continued to provide clinically meaningful benefit to patients with metastatic RET fusion–positive non–small cell lung cancer.